BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma

By afschroeder • August 8, 2026

Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer J, Parikh ND, Pillai A, Salem R, Sapisochin G, Tabrizian P, Yopp A, Yarchoan M; HCC-Live Steering Committee. BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026 Aug 7. doi: 10.1097/HEP.0000000000001834. Epub ahead of print. PMID: 42565685.

Tags: Hematology/Oncology, immunotherapy, liver cancer, locoregional therapy, Publications, Treatment

Related Posts

A compendium of next-generation patient-derived models for diverse cancers

ElHarouni D, Al-Jazrawe M, Choi S, Dede M, Hinoue T, Misek SA, Noh H, Zanella L, Tseng YY, Francies HE, Plenker D, Kyi CW, Perez-Mayoral[...]

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies

Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV,[...]